HitGen Teams Up with OrbiMed and Other Investors to Invest in Innovative Biotech Company Connexus Therapeutics Release Time：2026-09-20

HitGen Inc. (“HitGen”, SSE: 688222.SH) announced on September 17, 2026, that its wholly owned Hong Kong subsidiary, HitGen (HK) Ltd., has jointly invested in Connexus Therapeutics (“Connexus”) alongside OrbiMed Asia Partners, LAV, and Panku Capital Limited (a wholly owned subsidiary of Biokin Pharmaceutical). Connexus is a preclinical-stage biotechnology company focused on developing novel small molecule oncology therapeutics.

HitGen (HK) Ltd. is the founding shareholder of Connexus. Under the agreement, HitGen will acquire founding shares in Connexus through a multi-stage technology licensing arrangement. Connexus will establish its own team, operate independently, and assume responsibility for advancing the drug discovery research programs. Concurrently, Connexus has closed a Series A financing round with funding from OrbiMed Asia Partners and other investors. All parties will leverage their complementary strengths to advance the research programs and explore future pathways for global collaboration and value realization.

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen, said: “We are very pleased to partner with world-class life sciences investors OrbiMed Asia Partners and LAV, together with the industrial capital of Biokin Pharmaceutical, a leading innovative biopharmaceutical company, to jointly invest in Connexus, with an aim to advance the development of novel oncology therapies and accelerate the programs into clinical development. Going forward, HitGen will work with leading investors and industrial partners to explore more collaboration opportunities, continuously deliver original innovation, and bring more novel therapies to patients in need.”

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH) is dedicated to building a world-class innovative biopharmaceutical enterprise. Driven by the mission to advance human health and quality of life, it provides innovative therapeutic solutions to address unmet medical needs. Centered on its internationally leading DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics, and has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery and optimization engine that delivers both therapeutics molecules and tool molecules to the global pharmaceutical industry. Headquartered in Chengdu, China, HitGen maintains subsidiaries in Cambridge, UK, and Houston, USA, with its operational network spanning the globe. Through diversified and flexible business models including technical services, project out-licensing and product sales, the Company has forged extensive collaborations with a broad range of pharmaceutical and biotechnology companies, chemical firms, foundations, and research institutions. As of June 30, 2026, it has empowered over 700 clients globally and contributed to thousands of their innovative drug development projects. HitGen also advances multiple internal programmes at various clinical and preclinical stages. For more information, please visit www.hitgen.com.